

Deep learning prediction of likelihood of ICU admission and mortality in COVID-19 patients using clinical variables

Xiaoran Li¹ Equal first author, ¹, Peilin Ge¹ Equal first author, ¹, Jocelyn Zhu¹, Haifang Li¹, James Graham¹, Adam Singer², Paul S Richman³, Tim Q Duong⁴ Corresp.

¹ Department of Radiology, Renaissance School of Medicine, Stony Brook University, New York, Stony Brook, New York, United States

² Department of Emergency Medicine, Renaissance School of Medicine, Stony Brook University, New York, Stony Brook, New York, United States

³ Department of Medicine, Renaissance School of Medicine, Stony Brook University, New York, Stony Brook, New York, United States

⁴ Department of Radiology, Albert Einstein College of Medicine, Bronx, New York, United States

Corresponding Author: Tim Q Duong

Email address: tim.duong@einsteinmed.org

Background: This study aimed to develop a deep-learning model and a risk-score system using clinical variables to predict intensive care unit (ICU) admission and in-hospital mortality in COVID-19 patients. **Methods:** This retrospective study consisted of 5766 persons-under-investigation for COVID-19 between February 7, 2020, and May 4, 2020. Demographics, chronic comorbidities, vital signs, symptoms, and laboratory tests at admission were collected. A deep neural network model and a risk-score system were constructed to predict ICU admission and in-hospital mortality. Prediction performance used the receiver operating characteristic area under the curve (AUC). **Results:** The top ICU predictors were procalcitonin, lactate dehydrogenase, C-reactive protein, ferritin, and oxygen saturation. The top mortality predictors were age, lactate dehydrogenase, procalcitonin, cardiac troponin, C-reactive protein, and oxygen saturation. Age and troponin were unique top predictors for mortality but not ICU admission. The deep-learning model predicted ICU admission and mortality with an AUC of 0.780 [95% CI:0.760–0.785] and 0.844 [95% CI:0.839–0.848], respectively. The corresponding risk scores yielded an AUC of 0.728 [95% CI:0.726–0.729] and 0.848 [95% CI:0.847–0.849], respectively. **Conclusions:** Deep learning and the resultant risk score have the potential to provide frontline physicians with quantitative tools to stratify patients more effectively in time-sensitive and resource-constrained circumstances.

1 Manuscript Type: Original research

2

3 **Deep learning prediction of likelihood of ICU admission and mortality in COVID-19 patients using**
4 **clinical variables**

5

6 Xiaoran Li^{1*}, Peilin Ge^{1*}, Jocelyn Zhu^{1*}, Haifang Li¹, James Graham, Adam J. Singer², Paul S. Richman³,
7 Tim Q Duong⁴

8

*Co-first authors

9

10

11 ¹Department of Radiology, Renaissance School of Medicine, Stony Brook University, New York

12

13 ²Department of Emergency Medicine, Renaissance School of Medicine, Stony Brook University, New York

14

15 ³Department of Medicine, Renaissance School of Medicine, Stony Brook University, New York

16 ⁴Department of Radiology, Albert Einstein College of Medicine, Bronx, New York

17

18 Correspondence: Tim Duong, PhD, Radiology, ⁴Department of Radiology, Albert Einstein College of
19 Medicine, 111 E 210th St, Bronx, New York, Tim.duong@einsteinmed.org, T 718 920 6268

20

21 Word Count for Text: 2800

22 **Key words:** Machine learning, coronavirus, SARS-CoV-2, prediction model.

23

24 **ACKNOWLEDGEMENT**

25 We thank all healthcare professionals for their hard work being at the front line of the pandemic.

26 All authors had full access to data, and declared no conflict of interest, including financial interests,
27 activities, relationships, and affiliations. We report no sources of funding.

28

29 **Funding** None

30 **Disclaimer** NA

31 **Competing interests** none declared.

32 **Ethics approval.** Our institutional review board (Stony Brook University) approved this retrospective
33 study, and the requirement for informed consent was waived.

34

35 **Abbreviations:** alanine aminotransferase (ALT), C-reactive protein (CRP), lactate dehydrogenase
36 (LDH), white blood cells (WBC), real-time polymerase chain reaction (RT-PCR), area under the curve
37 (AUC)

38

39

40

41

42

43 **ABSTRACT**

44 **Background:** This study aimed to develop a deep-learning model and a risk-score system using clinical
45 variables to predict intensive care unit (ICU) admission and in-hospital mortality in COVID-19 patients.

46 **Methods:** This retrospective study consisted of 5766 persons-under-investigation for COVID-19 between
47 February 7, 2020, and May 4, 2020. Demographics, chronic comorbidities, vital signs, symptoms, and
48 laboratory tests at admission were collected. A deep neural network model and a risk-score system were
49 constructed to predict ICU admission and in-hospital mortality. Prediction performance used the receiver
50 operating characteristic area under the curve (AUC).

51 **Results:** The top ICU predictors were procalcitonin, lactate dehydrogenase, C-reactive protein, ferritin,
52 and oxygen saturation. The top mortality predictors were age, lactate dehydrogenase, procalcitonin,
53 cardiac troponin, C-reactive protein, and oxygen saturation. Age and troponin were unique top predictors
54 for mortality but not ICU admission. The deep-learning model predicted ICU admission and mortality
55 with an AUC of 0.780 [95% CI:0.760–0.785] and 0.844 [95% CI:0.839–0.848], respectively. The
56 corresponding risk scores yielded an AUC of 0.728 [95% CI:0.726–0.729] and 0.848 [95% CI:0.847–
57 0.849], respectively.

58 **Conclusions:** Deep learning and the resultant risk score have the potential to provide frontline physicians
59 with quantitative tools to stratify patients more effectively in time-sensitive and resource-constrained
60 circumstances.

61

62 INTRODUCTION

63 Since the first reports of severe respiratory illness caused by coronavirus disease 2019 (COVID-
64 19) in Wuhan, China in mid-December 2019 (Huang et al. 2020; Zhu et al. 2020), over 6.2 million
65 individuals have been infected, resulting in over 370,000 deaths worldwide (May 31, 2020). The actual
66 numbers are likely to be much higher due to testing shortages and under-reporting (Yelin et al. 2020).
67 Many patients have mild or asymptomatic infections, while others deteriorate rapidly with multi-organ
68 failure. There will likely be recurrence and secondary waves of this pandemic (Leung et al. 2020).

69 A large array of clinical and demographic variables associated with COVID-19 infection have
70 been identified (see reviews (Brown et al. 2020; Cao et al. 2020; Rodriguez-Morales et al. 2020)). A few
71 of these have been associated with high likelihood of critical illness or mortality. There are however no
72 established prognostic models that reliably predict the need for escalated (intensive care unit, ICU) care or
73 mortality due to COVID-19 infection. Lacking this, effective triage of patients is challenging in a
74 resource-constrained environment. The problem is further magnified by the poor sensitivity (Kim et al.
75 2020, in press) and a few day turnaround time (Yelin I 2020) of the most commonly used reverse-
76 transcriptase polymerase chain reaction (RT-PCR) test, during which time patients are assumed COVID-
77 19 positive. This problem strains the resources of many hospitals and highlights the need for effective
78 tools to anticipate patients' progression and properly triage patients.

79 The goal of this study was to develop a deep-learning algorithm (in contrast to previous methods)
80 to identify the top, statistically significant predictors amongst the large array of clinical variables at
81 admission to predict the likelihood of ICU admission and in-hospital mortality in COVID-19 patients. We
82 further developed a simplified risk-score model to predict the likelihood of ICU admission and in-hospital
83 mortality.

84

85 METHODS

86 Study population

87 This retrospective study was approved by Institutional Review Board with exemption of informed
88 consent and HIPAA waiver (Stony Brook University Hospital, IRB-2020-00207). Stony Brook University
89 Hospital, the only academic hospital serving Suffolk county, about 40 miles east of New York City, was
90 one of the hardest hit counties in the country at the time of this writing. The COVID-19 Persons Under
91 Investigation (PUI) registry consisted of 5766 patients from February 7th, 2020 to May 4th, 2020. Only
92 patients who were diagnosed by positive tests of real-time polymerase chain reaction (RT-PCR) for
93 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were included in the study.
94 Demographic information, chronic comorbidities, imaging findings, vital signs, symptoms, and laboratory
95 tests at admission were collected. Imaging findings were extracted from patient chart review, which

96 included information provided by radiology report as part of standard of care. The primary outcome was
97 ICU admission versus general floor admission, and the secondary outcome was in-hospital mortality
98 versus discharge. Mortality outside of hospital after discharge was not obtained.

99 **Figure 1** shows the flowchart of patient selection. Of the 2594 confirmed COVID-19 positive
100 cases, all 1108 hospitalized COVID-19 positive patients were used in our analysis. Seventy-seven (77)
101 patients were admitted to the ICU directly and an additional 194 patients were subsequently upgraded to
102 an ICU from a general floor. Among these 271 ICU patients, 108 were discharged alive, 77 expired
103 during the hospitalization and the other 86 are still in the hospital at the time of this analysis. Comparison
104 was made to 837 general admissions who did not receive ICU care, among whom 772 patients were
105 discharged alive and 65 expired during the hospitalization (none remained in the hospital).

106

107 Data preprocessing

108 Two patients were excluded from machine learning analysis for missing categorical variables.
109 Brain natriuretic peptide (BNP) was missing from >15% of patients, thus they were excluded from
110 machine learning analysis. For the rest of the laboratory variables, missing data (in <5% of patients) was
111 imputed with predictive mean modeling using the Multivariate Imputation by Chained Equations in R
112 (statistical analysis software, version 4.0) (van Buuren & Groothuis-Oudshoorn 2011).

113

114 Deep neural network prediction model

115 Ranking of clinical variables of categorical or numerical values were made using the Boruta, a
116 statistical software (Kursa & Rudnicki 2010). Boruta ranks feature importance using the Random Forest
117 method. In this decision tree-based method, the quantitative measure of importance is the Gini feature of
118 importance, which counts the times that a feature is used to split a node of a decision tree, statistically
119 weighted by the number of instances the node splits. In the DNN model, the top predictors were those that
120 demonstrated statistical significance using built-in statistical methods within the Boruta algorithm.

121 A correlation coefficient >0.5 from collinearity analysis was used to exclude correlated variables
122 from machine learning analysis. Note that none of the top features we used in the final analysis
123 demonstrated strong correlation with other features. Thus, no top features were removed as a result. A
124 deep neural network (DNN) was constructed to predict ICU admission and mortality using five fully
125 connected dense layers (Chen et al. 2020). The top clinical predictors were input parameters, determined
126 by testing subsets of these parameters, and ICU admission and mortality were outcome parameters. The
127 DNN model used 5 hidden layers with 6, 8, 16, 8, 4 neurons respectively. We explored a few models
128 using a range of number (3-7) of layers, and the 5-layer model yielded the optimal validation result. ReLU
129 activation function for the hidden layers, the sigmoid activation function for the output layer, and the

130 “he_normal” normalization scheme were applied. In the model training process, we used Adam optimizer,
131 mean squared error as the cost function, a default learning rate of 0.01, and number of epochs of 100. The
132 reported results yielded from the average of 5 consecutive runs. The dataset was randomly split into 90%
133 training data and 10% testing data. ICU admission and mortality results were categorized using a binary
134 classification. To minimize overfitting, we employed 5-fold cross-validation, ranked and removed less
135 important features using correlation analysis and based on statistical significance by Boruta. We also
136 employed regularization and stopped the training process at 100 epochs.

137

138 Risk score model

139 Risk-score systems were constructed using the top independent clinical variables to predict ICU
140 admission and mortality. For risk score, the mixed Generalized Additive Model was used to plot the
141 probability of ICU admission and mortality for each clinical variable (Wood 2001). Different cutoff
142 points were evaluated where the chosen cutoff points yielded the optimal distribution (not skewed to high
143 or low scores) of the risk score model. The corresponding numerical values of each top feature at
144 probability of 0.3 for ICU and 0.2 for mortality were found to be the optimal cutoff values for the risk
145 score model. Each of the top variables was assigned a weight of one point if the clinical measurement was
146 above the probability cutoff. The risk score ranged from 0 to 5 for ICU admission and 0 to 6 for mortality
147 (which were chosen based on statistical significance, see Results).

148

149 Statistical analysis and performance evaluation

150 Statistical analysis was performed in SPSS v26 and in R (statistical analysis software 4.0). Group
151 comparisons of categorical variables in frequencies and percentages used the chi-square test or Fisher
152 exact test. Group comparison of continuous variables in medians and interquartile ranges (IQR) used the
153 Mann-Whitney U test. A p value < 0.05 was considered to be statistically significant. For performance
154 evaluation, data were split 90% for training and 10% for testing. Prediction performance was evaluated by
155 calculating the area under the curve (AUC) of the receiver operating characteristic (ROC) curve,
156 accuracy, sensitivity, specificity, precision, recall, negative predictive value (NPV), positive predictive
157 value (PPV) and F1 score (a harmonic mean of precision and recall). The average ROC analysis was
158 repeated with five runs. In risk score models, SPSS was used to cross-check statistical significance of the
159 top features, in which all top features used in the final analysis of risk score model had a p < 0.001.

160

161

162 **RESULTS**

163

164 Clinical variables associated with ICU admission

165 **Table 1** summarizes the demographic characteristics, vital signs, comorbidities, and laboratory
166 data for the ICU (n=271) and non-ICU (n=837) group. The median age of the ICU group was lower than
167 that of the general admission group (59 years [IQR:49-71] versus 62 years [IQR:50-76], p=0.027).
168 Disproportionally more males were admitted to the ICU (67.5% vs 32.5%, p<0.001). History of cancer
169 was the only comorbidity that was significantly associated with ICU admission (P=0.016).

170 All measured vital signs were significantly different between the ICU group and the non-ICU
171 group. The ICU group had higher heart rate, respiratory rate and temperature, but lower systolic blood
172 pressure and oxygen saturation (p<0.05). The ICU group had higher alanine aminotransferase (ALT), C-
173 reactive protein (CRP), D-dimer, ferritin, lactate dehydrogenase (LDH), white blood cells (WBC), and
174 procalcitonin (p<0.05) and lower lymphocyte counts (p<0.05). Cardiac troponin and BNP were not
175 significantly different between groups (p>0.05).

176 The symptom of dyspnea was significantly associated with ICU admission (p=0.001). Patients
177 admitted to ICU were more likely to present with abnormal chest x-ray (p<0.001), and more likely to
178 have bilateral chest x-ray abnormalities on presentation, compared to that of general admission group
179 (p<0.001).

180

181 Prediction models for ICU admission

182 **Figure 2** shows the ranking of the clinical variables associated with ICU admission. The top 5
183 statistically significant predictors of ICU admission were procalcitonin, LDH, CRP, ferritin, and SpO₂. A
184 deep neural network predictive model for mortality was constructed using the top clinical variables and
185 trained using the training dataset and tested on an independent testing dataset. The ROC and confusion
186 matrix of the testing dataset are shown in **Figure 3**. The performance of the DNN model yielded an AUC
187 = 0.780 [95% CI:0.760-0.785], sensitivity = 0.760, specificity = 0.709, and F1 score = 0.551 in predicting
188 ICU admission for the testing set (**Table 2**).

189 A risk score system was constructed (training data set) using the top five statistically significant
190 clinical variables, with 1 point given for each variable meeting the following criteria:
191 procalcitonin>0.5ng/mL, LDH >487U/L and <12586.7U/L, CRP>14.2mg/dL, ferritin>1250ng/mL and
192 <13080.5ng/mL, and SpO₂<88.8%. Odds ratios of procalcitonin, LDH, CRP, ferritin, and SpO₂ for ICU
193 admission were 3.062, 3.846, 3.001, 2.449, and 3.665, respectively. **Figure 4** shows the results for the
194 testing data set using the risk score system. ICU admission rate increased with increasing risk scores. The
195 performance of the risk score yielded an AUC of 0.728 [95% CI:0.726-0.729] for predicting ICU
196 admission for the testing data set.

197

198 Clinical variables associated with mortality

199 **Table 3** summarizes the demographic data, vital signs, comorbidities, and laboratory data for the
200 non-survivors (n=142) and survivors (n=880) group. The median age of the non-survivor group was
201 higher than that of the survivor group (76 years [IQR:66-84] versus 59 years [IQR:49-72], $p<0.001$).
202 There was a disproportionately higher mortality rate in males (65.5% vs 34.5%, $p=0.014$). Of the
203 comorbidities, hypertension, coronary artery disease, heart failure, chronic obstructive pulmonary disease,
204 smoking history, and chronic kidney disease were significantly different between groups ($p<0.05$).

205 Among vital signs, tachypnea and hypoxemia were significantly different between groups at
206 presentation ($p<0.05$). The expired cohort had higher BNP, CRP, D-dimer, ferritin, LDH, WBC,
207 procalcitonin, and cardiac troponin but lower lymphocytes ($p<0.05$). ALT was not significantly different
208 between groups.

209 Among the symptoms, cough, myalgia, nausea or vomiting, chest discomfort, fatigue, fever, loss
210 of taste, and headache were significantly different between groups ($p<0.05$). There was no significant
211 difference in x-ray findings between groups at presentation.

212

213 Prediction models for mortality

214 The top 6 statistically significant predictors of mortality were age, LDH, procalcitonin, troponin,
215 CRP, and SpO2 (**Figure 5**). A deep neural network predictive model for mortality was constructed using
216 the top clinical variables and trained using the training data set. The ROC and confusion matrix are shown
217 in **Figure 6**. The performance of the DNN model yielded an AUC of 0.844 [95% CI:0.839-0.848],
218 sensitivity = 0.750, specificity = 0.872, and F1 score = 0.616 for the testing dataset (**Table 4**).

219 A risk score system was constructed (training data set) using the top 6 statistically significant
220 clinical variables to predict mortality. The thresholds for the risk scores were: age >71 years, LDH
221 >487U/L, procalcitonin >1.1ng/mL, troponin >0.03ng/mL, CRP >17mg/dL, and SpO2 <88%. Odds ratios
222 of age, LDH, procalcitonin, troponin, CRP, and SpO2 for mortality were 4.301, 3.418, 6.232, 5.253,
223 4.240, and 3.750, respectively. Higher mortality rate was associated with higher risk scores for the testing
224 set (**Figure 7**). The performance of the risk score yielded an AUC of 0.848 [95% CI:0.847-0.849] in
225 predicting mortality for the testing set.

226

227 **DISCUSSION**

228 Mining a large cohort of COVID-19 patients in the United States, deep-learning and resultant risk
229 score models identified the top predictors of ICU admission in COVID-19 to be the admission levels of
230 procalcitonin, LDH, CRP, ferritin, and SpO2; the top predictors of mortality were age, LDH,
231 procalcitonin, cardiac troponin, CRP, and SpO2. Predictive models were developed using deep neural

232 network of the top predictors, yielding an AUC of 0.779 and 0.882 for predicting ICU admission and
233 mortality, respectively. The corresponding simplified risk scores yielded an AUC of 0.728 and 0.848,
234 respectively.

235

236 The association between these biomarkers and poor outcomes in COVID-19 victims is
237 biologically plausible: procalcitonin is elevated during bacterial infection, but less so during viral
238 infection, suggesting that bacterial co-infection leads to worse outcome in COVID-19 patients (Assicot et
239 al. 1993). LDH reflects tissue damage (Huang et al. 2020; Zhu et al. 2020), while CRP is indicative of
240 inflammation (Gabay & Kushner 1999). Elevated ferritin is associated with acute respiratory distress
241 syndrome (ARDS) (Connelly et al. 1997) and may be a marker of aberrant iron metabolism that could
242 render the lungs susceptible to oxidative damage (Mumby et al. 2004). Ferritin may reflect
243 hyperinflammation associated with a cytokine storm and multi-organ failure (Mehta et al. 2020). Low
244 SpO₂ indicates failure of the lungs to oxygenate blood effectively, leading to tissue hypoxia (Connelly et
245 al. 1997). Elevated cardiac troponin indicates cardiac injury (Huang et al. 2020). Although these variables
246 have been previously associated with COVID-19 infection, most previous studies did not rank these
247 clinical variables, or develop predictive models or risk scores to predict ICU admission or mortality. Not
248 surprisingly, some of the same biomarkers in our study predicted both the need for ICU admission and
249 likelihood of mortality. However, age and admission troponin level were uniquely predictive of mortality,
250 indicating older age and cardiac issues are associated with higher rate of mortality in COVID-19
251 infection.

252 It is notable that individual comorbidities did not rank high in predicting ICU admission and
253 mortality. Specifically, a history of heart failure, COPD, and coronary artery disease only ranked 7th, 11th
254 and 14th respectively for predicting mortality. Similarly, the patients' symptoms and vital signs (other than
255 SpO₂) at the time of admission were not found to be the top predictors of poor outcome. Although some
256 comorbidities have been reported to be associated with critical illness and mortality, most previously
257 studies did not rank their importance with respect to other laboratory variables.

258 Our predictive AUC performance for ICU admission was poorer than that for mortality. We
259 speculate this might be due to variability in triage decision-making to send patients to ICU among
260 frontline clinicians. For both predictions, precision, PPV and F1 scores were comparatively low, which
261 was not unexpected due to the imbalanced sample sizes between the two groups as well as small sample
262 sizes. Further studies are warranted.

263 While a large number of studies have previously identified clinical variables associated with the
264 severity of COVID-19 infection, only a few studies have attempted to develop a predictive or risk score
265 model to predict mortality and disease severity. Jiang *et al.* used supervised learning (not deep learning)

266 and found mildly elevated alanine aminotransferase, myalgias, and hemoglobin at presentation to be
267 predictive of severe ARDS of COVID-19 with 70% to 80% accuracy. This study had small, non-uniform,
268 heterogeneous clinical variables, obtained from different hospitals (Jiang et al. 2020). Ji *et al.* used
269 logistic regression to predict stable versus progressive COVID-19 patients (n=208) based on whether their
270 conditions worsened during hospitalization (Ji et al. 2020). They reported comorbidities, older age, lower
271 lymphocyte and higher lactate dehydrogenase at presentation to be independent high-risk factors for
272 COVID-19 progression but did not develop a risk score. A nomogram of these 4 factors yielded a
273 concordance index of 0.86. Yan *et al.* utilized supervised machine learning to predict critical COVID-19
274 at admission using presence of X-ray abnormality, cancer history, age, neutrophil/lymphocyte ratio, LDH,
275 dyspnea, bilirubin, unconsciousness and number of comorbidities (Yan et al. 2020, in press). They
276 reported an AUC of 0.88. Yuan et al. went one step further to predict mortality more than 12 days in
277 advance with >90% accuracy across all cohorts. Moreover, their Kaplan-Meier score shows that
278 patients upon admission could clearly be differentiated into low, medium or high risk. They created
279 a simple risk score system, and validated using multiple independent cohorts (Yuan et al. 2020).

280 Our approach used a deep-learning algorithm which is novel and has distinct advantages over
281 logistic regression and supervised learning approach. Deep learning is increasingly being used in
282 medicine (Deo 2015; Santos et al. 2019; Tschandl et al. 2019). In contrast to conventional analysis
283 methods, which specify the relationships amongst data elements to outcomes, machine learning employs
284 computer algorithms to identify relationships amongst different data elements to inform outcomes without
285 the need to specify such relationships *a priori*. Deep learning can outperform human experts in
286 performing many tasks in medicine (Killock 2020). In addition to approximating physician skills, Deep
287 learning can also detect novel relationships not readily apparent to human perception, especially in large,
288 complex, and longitudinal datasets. Disadvantages of deep learning methods are that it requires
289 comparatively large sample size, there is a potential of overfitting, and the complex relations could make
290 deep learning results difficult to interpret, amongst others. In addition, we devised a simplified practical
291 risk score adds practical utility to these findings. Although we ranked all variables and explicitly listed 10
292 or 15 top variables, we built the predictive model and risk score model using only the top 5 variables to
293 simplify and increase translation potential in the clinical settings. The excellent prediction performances
294 using a few clinical variables are encouraging.

295

296 This study has several limitations in addition to those mentioned above. This is a retrospective
297 study carried out in a single hospital. These findings need to be replicated in large and multi-institutional
298 settings for generalizability. We only analyzed clinical variables at admission. Longitudinal changes of
299 these clinical variables need to be studied. As in all observational studies, other residual confounders may

300 exist that were not accounted for in our analysis. Future prospective studies validating our predictive
301 models and scores are warranted.

302

303 **CONCLUSION**

304 We implemented a deep-learning algorithm and a risk score model to predict the likelihood of ICU
305 admission and mortality in COVID-19 patients. Our predictive model and risk score model can be easily
306 retrained with additional data, new local data, as well as additional clinical variables. This approach has
307 the potential to provide frontline physicians with a simple and objective tool to stratify patients based on
308 risks so that COVID-19 patients can be triaged more effectively in time-sensitive, stressful and potentially
309 resource-constrained environments.

310

311 **ACKNOWLEDGEMENT**

312 The work has been approved by Stony Brook Institutional Review Board. We thank all healthcare
313 Professionals for their hard work being at the front line of the pandemic. All authors had full access to
314 data, and declared no conflict of interest, including financial interests, activities, relationships, and
315 affiliations. We report no sources of funding.

316

317

318

319

320

321 REFERENCES

- 322 <https://coronavirus.jhu.edu/map.html>. assessed Jul 11, 2020.
- 323 Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, and Bohuon C. 1993. High serum procalcitonin
324 concentrations in patients with sepsis and infection. *Lancet* 341:515-518. 10.1016/0140-6736(93)90277-n
- 325 Brown RAC, Barnard J, Harris-Skillman E, Harbinson B, Dunne B, Drake J, Roche S, Harris E, Gunnel J, Frost J,
326 Angus B, and Hodgson S. 2020. Lymphocytopenia is associated with severe SARS-CoV-2 disease: A
327 Systematic Review and Meta-Analysis of Clinical Data. *medRxiv:2020.2004.2014.20064659*.
328 10.1101/2020.04.14.20064659
- 329 Cao Y, Liu X, Xiong L, and Cai K. 2020. Imaging and Clinical Features of Patients With 2019 Novel Coronavirus
330 SARS-CoV-2: A systematic review and meta-analysis. *Journal of Medical Virology* 03:03.
331 <https://dx.doi.org/10.1002/jmv.25822>
- 332 Chen Z, Pang M, Zhao Z, Li S, Miao R, Zhang Y, Feng X, Feng X, Zhang Y, Duan M, Huang L, and Zhou F. 2020.
333 Feature selection may improve deep neural networks for the bioinformatics problems. *Bioinformatics*
334 36:1542-1552. 10.1093/bioinformatics/btz763
- 335 Connelly KG, Moss M, Parsons PE, Moore EE, Moore FA, Giclas PC, Seligman PA, and Repine JE. 1997. Serum
336 ferritin as a predictor of the acute respiratory distress syndrome. *American Journal of Respiratory &*
337 *Critical Care Medicine* 155:21-25. 10.1164/ajrccm.155.1.9001283
- 338 Deo RC. 2015. Machine Learning in Medicine. *Circulation* 132:1920-1930.
339 10.1161/CIRCULATIONAHA.115.001593
- 340 Gabay C, and Kushner I. 1999. Acute-phase proteins and other systemic responses to inflammation. *New England*
341 *Journal of Medicine* 340:448-454. 10.1056/NEJM199902113400607
- 342 Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W,
343 Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, and
344 Cao B. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*
345 395:497-506. 10.1016/S0140-6736(20)30183-5
- 346 Ji D, Zhang D, Xu J, Chen Z, Yang T, Zhao P, Chen G, Cheng G, Wang Y, Bi J, Tan L, Lau G, and Qin E. 2020.
347 Prediction for Progression Risk in Patients with COVID-19 Pneumonia: the CALL Score. *Clinical*
348 *Infectious Diseases* 09:09. <https://dx.doi.org/10.1093/cid/ciaa414>
- 349 Jiang X, Coffee2 M, Bari A, Wang J, Jiang X, Huang J, Shi J, Dai J, Cai J, Zhang, T., Wu Z, He G, and Huang Y.
350 2020. Towards an Artificial Intelligence Framework for Data-Driven Prediction of Coronavirus Clinical
351 Severity. *Computers, Materials & Continua* 63:537-551.
- 352 Killock D. 2020. AI outperforms radiologists in mammographic screening. *Nat Rev Clin Oncol* 17:134.
353 10.1038/s41571-020-0329-7
- 354 Kim HA, Hong HE, and Yoon SH. 2020, in press. Diagnostic performance of CT and RT-PCR for COVID-19: A
355 meta-analysis. *Radiology*.
- 356 Kursa MB, and Rudnicki WR. 2010. Feature Selection with the Boruta Package. *Journal of Statistical Software*
357 36:1-13.
- 358 Leung K, Wu JT, Liu D, and Leung GM. 2020. First-wave COVID-19 transmissibility and severity in China outside
359 Hubei after control measures, and second-wave scenario planning: a modelling impact assessment. *The*
360 *Lancet* 395:1382-1393. 10.1016/S0140-6736(20)30746-7
- 361 Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, and Hlh Across Speciality Collaboration
362 UK. 2020. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* 395:1033-
363 1034. 10.1016/S0140-6736(20)30628-0
- 364 Mumby S, Upton RL, Chen Y, Stanford SJ, Quinlan GJ, Nicholson AG, Gutteridge JM, Lamb NJ, and Evans TW.
365 2004. Lung heme oxygenase-1 is elevated in acute respiratory distress syndrome. *Crit Care Med* 32:1130-
366 1135. 10.1097/01.ccm.0000124869.86399.f2
- 367 Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-
368 Antezana JP, Alvarado-Arnez LE, Bonilla-Aldana DK, Franco-Paredes C, and Henao-Martinez AF. 2020.
369 Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. *Travel*
370 *medicine and infectious disease*:101623. 10.1016/j.tmaid.2020.101623
- 371 Santos MK, Ferreira Junior JR, Wada DT, Tenorio APM, Barbosa MHN, and Marques PMA. 2019. Artificial
372 intelligence, machine learning, computer-aided diagnosis, and radiomics: advances in imaging towards to
373 precision medicine. *Radiol Bras* 52:387-396. 10.1590/0100-3984.2019.0049

374 Tschandl P, Codella N, Akay BN, Argenziano G, Braun RP, Cabo H, Gutman D, Halpern A, Helba B, Hofmann-
375 Wellenhof R, Lallas A, Lapins J, Longo C, Malvehy J, Marchetti MA, Marghoob A, Menzies S, Oakley A,
376 Paoli J, Puig S, Rinner C, Rosendahl C, Scope A, Sinz C, Soyer HP, Thomas L, Zalaudek I, and Kittler H.
377 2019. Comparison of the accuracy of human readers versus machine-learning algorithms for pigmented
378 skin lesion classification: an open, web-based, international, diagnostic study. *Lancet Oncol* 20:938-947.
379 10.1016/S1470-2045(19)30333-X

380 van Buuren S, and Groothuis-Oudshoorn K. 2011. mice: Multivariate Imputation by Chained Equations in R.
381 *Journal of Statistical Software* 45:1-67.

382 Wood SN. 2001. mgcv: GAMs and generalized ridge regression for R. 1.

383 Yan L, Zhang HT, Goncalves J, Xiao Y, Wang M, Guo Y, Sun C, Tang X, Jing L, Zhang M, Huang X, Xiao Y, Cao
384 H, Chen Y, Ren T, Wang F, Xiao Y, Huang S, Tan X, Huang N, Jiao B, Cheng C, Zhang Y, Luo A,
385 Mombaerts L, J. J, and Cao Z. 2020, in press. An interpretable mortality prediction model for COVID-19
386 patients. *Nat Machine Intelligence*.

387 Yelin I, Aharony N, Shaer-Tamar E, Argoetti A, Messer E, Berenbaum D, Shafran E, Kuzli A, Gandali N, and
388 Hashimshony T. 2020. Evaluation of COVID-19 RT-qPCR test in multi-sample pools. medRxiv.

389 Yelin I AN, Tamer ES, Argoetti, Messer E, Berenbaum, Shafran E, Kuzli A, Gandali, Hashimshony T, Mandel-
390 Gutfreund Y, Halberthal M, Geffen Y, Szwarcwort-Cohen M, Kishony R. 2020. Evaluation of COVID-19
391 RT-qPCR test in multi-sample pools. <https://doi.org/10.1101/2020.03.26.20039438>

392 Yuan Y, Sun C, Tang X, Cheng C, Mombaerts L, Wang M, Hu T, Sun C, Guo Y, Li X, Xu H, Ren T, Xiao Y, Xiao
393 Y, Zhu H, Chen C, Liu Y, Liang Z, Cao Z, Zhang HT, Paschaldis IC, Liu Q, Goncalves J, Zhong Q, and Yan
394 L. 2020. Development and validation of a prognostic risk score system for COVID-19 inpatients: A multi-
395 center retrospective study in China. *Pre-print*. 10.21203/rs.3.rs-41151/v1

396 Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D,
397 Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus I, and Research T. 2020. A Novel Coronavirus
398 from Patients with Pneumonia in China, 2019. *N Engl J Med* 382:727-733. 10.1056/NEJMoa2001017

399

400 **Figure legends**

401

402

403 **Figure 1.** Patient selection flowchart.

404

405 **Figure 2.** Ranking of clinical variables for predicting ICU admission by Boruta algorithm. The x-axis is
406 attribute of level of importance, where a larger number indicates relatively higher importance. The y-axis
407 are laboratory test variables. The top statistically significant predictors were: procalcitonin, LDH, CRP,
408 ferritin, SpO₂, lymphocytes, respiratory rate, systolic blood pressure, age and ALT. The top 10 variables
409 were significant.

410

411 **Figure 3.** ROC and confusion matrix for prediction of ICU admission of the DNN model.

412

413 **Figure 4.** Risk score stratification for ICU admission. Scores ranged from 0 to 5, with 0 indicating the
414 lowest risk and 5 being the highest risk of mortality. The numbers in the bar indicate the number of
415 patients in the ICU (red) and non-ICU (blue) that were correctly predicted in the testing dataset.

416

417 **Figure 5.** Ranking of clinical variables for predicting mortality by Boruta algorithm. The x-axis is
418 attribute of level of importance, where a larger number indicates relatively higher importance. The y-axis
419 are laboratory test variables. The top statistically significant predictors were: age, LDH, procalcitonin,
420 troponin, CRP, SpO₂, history of heart failure, respiratory rate, lymphocytes, ferritin, history of COPD, D-
421 dimer, ALT, history of coronary heart disease, and systolic blood pressure. The top 15 variables were
422 significant.

423

424 **Figure 6.** ROC and confusion matrix for prediction of mortality of the DNN model.

425

426 **Figure 7.** Risk score stratification for mortality. Scores ranged from 0 to 6, with 0 indicating the lowest
427 risk and 6 being the highest risk of mortality. The numbers in the bar indicate the number of patients in
428 the ICU (red) and non-ICU (blue) that were correctly predicted in the testing dataset.

429

430

Figure 1

Patient selection flowchart.

Patient selection flowchart.




Figure 2

Ranking of clinical variables for predicting ICU admission

Ranking of clinical variables for predicting ICU admission by Boruta algorithm. The x-axis is attribute of level of importance, where a larger number indicates relatively higher importance. The y-axis are laboratory test variables. The top statistically significant predictors were: procalcitonin, LDH, CRP, ferritin, SpO2, lymphocytes, respiratory rate, systolic blood pressure, age and ALT. The top 10 variables were significant.

ICU admission





Figure 3

ROC and confusion matrix for prediction of ICU admission

(A) ROC and (B) confusion matrix for prediction of ICU admission of the DNN model.



(B)

	Predicted ICU	Predicted non-ICU
Actual ICU	19	6
Actual non-ICU	25	61

Figure 4

Risk score stratification for ICU admission

Risk score stratification for ICU admission. Scores ranged from 0 to 5, with 0 indicating the lowest risk and 5 being the highest risk of mortality. The numbers in the bar indicate the number of patients in the ICU (red) and non-ICU (blue) that were correctly predicted in the testing dataset.




Figure 5

Ranking of clinical variables for predicting mortality.

Ranking of clinical variables for predicting mortality by Boruta algorithm. The x-axis is attribute of level of importance, where a larger number indicates relatively higher importance. The y-axis are laboratory test variables. The top statistically significant predictors were: age, LDH, procalcitonin, troponin, CRP, SpO₂, history of heart failure, respiratory rate, lymphocytes, ferritin, history of COPD, D-dimer, ALT, history of coronary heart disease, and systolic blood pressure. The top 15 variables were significant.

Mortality





Figure 6

ROC and confusion matrix for prediction of mortality

(A) ROC and (B) confusion matrix for prediction of mortality of the DNN model.

(A)



(B)

	Predicted death	Predicted survival
Actual death	12	4
Actual survival	11	75

Figure 7

Risk score stratification for mortality

Risk score stratification for mortality. Scores ranged from 0 to 6, with 0 indicating the lowest risk and 6 being the highest risk of mortality. The numbers in the bar indicate the number of patients in the ICU (red) and non-ICU (blue) that were correctly predicted in the testing dataset.




Table 1 (on next page)

Demographic characteristics, comorbidities, symptoms, imaging findings, vital signs, and laboratory findings of ICU versus non-ICU patients.

Demographic characteristics, comorbidities, symptoms, imaging findings, vital signs, and laboratory findings of ICU versus non-ICU patients. Group comparison of categorical variables in frequencies and percentages used χ^2 test or Fisher exact tests. Group comparison of continuous variables in medians and interquartile ranges (IQR) used the Mann-Whitney U test.

- 1 **Table 1.** Demographic characteristics, comorbidities, symptoms, imaging findings, vital signs, and
- 2 laboratory findings of ICU versus non-ICU patients. Group comparison of categorical variables in
- 3 frequencies and percentages used χ^2 test or Fisher exact tests. Group comparison of continuous variables
- 4 in medians and interquartile ranges (IQR) used the Mann-Whitney U test.

	Patients, No. (%)		p value
	ICU (n=271)	Non-ICU (n=837)	
Demographics			
Age, median (range), y	59 (49, 71)	62 (50,76)	0.027
Sex			<0.001
Male	183 (67.5%)	452 (54.0%)	
Female	88 (32.5%)	385 (46.0%)	
Ethnicity			0.153
Hispanic/Latino	78 (28.8%)	223 (26.6%)	
Non-Hispanic/Latino	148 (54.6%)	507 (60.6%)	
Unknown	45 (16.6%)	107 (12.8%)	
Race			0.003
Caucasian	123 (45.4%)	453 (54.1%)	
African American	13 (4.8%)	61 (7.3%)	
Asian	20 (7.4%)	26 (3.1%)	
American Indian/Alaska Native	2 (0.7%)	2 (0.2%)	
Native Hawaiian or other Pacific Islander	0	1 (0.1%)	
More than One Race	0	5 (0.6%)	
Unknown/Not Reported	113 (41.7%)	289 (34.5%)	
Comorbidities			
Smoking history	61 (22.6%)	214 (25.6%)	0.332
Diabetes	80 (29.5%)	220 (26.3%)	0.308
Hypertension	126 (46.5%)	412 (49.3%)	0.442
Asthma	23 (8.5%)	43 (5.1%)	0.054
COPD	39 (14.4%)	126 (15.1%)	0.845
Coronary artery disease	17 (6.3%)	76 (9.1%)	0.166
Heart failure	18 (6.6%)	62 (7.4%)	0.787
Cancer	15 (5.5%)	88 (10.5%)	0.016
Immunosuppression	20 (7.4%)	64 (7.7%)	1.000
Chronic kidney disease	20 (7.4%)	81 (9.7%)	0.276
Symptoms			
Fever	191 (70.5%)	547 (65.4%)	0.138
Cough	191 (70.5%)	564 (67.4%)	0.368
Shortness of breath	210 (77.5%)	557 (66.5%)	0.001
Fatigue	56 (20.7%)	201 (24.0%)	0.282
Sputum	25 (9.2%)	50 (6.0%)	0.071
Myalgia	61 (22.5%)	192 (22.9%)	0.934
Diarrhea	60 (22.1%)	201 (24.0%)	0.565
Nausea or vomiting	48 (17.7%)	176 (21.0%)	0.258

Sore throat	21 (7.7%)	61 (7.3%)	0.790
Rhinorrhea	14 (5.2%)	36 (4.3%)	0.613
Loss of smell	11 (4.1%)	34 (4.1%)	1.000
Loss of taste	12 (4.4%)	42 (5.0%)	0.871
Headache	80 (9.6%)	28 (10.3%)	0.724
Chest discomfort or chest pain	43 (15.9%)	133 (15.9%)	1.000
Imaging studies			
Abnormal chest x-ray results	227 (92.1%)	694 (83.6%)	<0.001
Chest x-ray findings			<0.001
Unilateral	26 (10.7%)	140 (20.7%)	
Bilateral	218 (89.3%)	536 (79.3%)	
Vital signs, median (IQR)			
Heart Rate, bpm	100 (87, 115)	98 (83, 110)	0.003
Respiratory rate, rate/min	23 (18, 30)	20 (18, 24)	<0.001
SpO ₂ %	93 (87, 96)	94 (92, 97)	<0.001
Systolic blood pressure, mmHg	122 (108, 137)	127 (114, 144)	0.003
Temperature, °C	37.4 (36.9, 38.3)	37.3 (36.9, 38.0)	0.021
Laboratory findings at admission, median (IQR)			
Alanine aminotransferase, U/L	37 (22, 59)	29 (17, 51)	<0.001
Brain natriuretic peptide, pg/mL	276 (81, 1123)	212 (53, 1143)	0.177
C-reactive protein, mg/dL	12.8 (6.9, 22.1)	7.2 (3.2, 13.3)	<0.001
D-dimer, ng/mL	401 (257, 831)	353 (217, 657)	0.012
Ferritin, ng/mL	1132 (582, 1867)	613 (289, 1234)	<0.001
Lactate dehydrogenase, U/L	436 (332, 593)	332 (257, 433)	<0.001
WBC, x10 ³ /ml	8.1 (6.1, 11.6)	7.3 (5.5, 9.4)	0.001
Lymphocytes%	10.6 (6.1, 15.4)	13.1 (8.4, 19.5)	<0.001
Procalcitonin, ng/mL	0.29 (0.16, 0.77)	0.15 (0.09, 0.28)	<0.001
Troponin, ng/mL	0.01 (0.01, 0.01)	0.01 (0.01, 0.01)	0.596

5 Abbreviation: COPD, chronic obstructive pulmonary disease. IQR, interquartile range. SpO₂, oxygen
6 saturation.

7

8 SI conversion factors: To convert alanine aminotransferase and lactate dehydrogenase to microkatal per
9 liter, multiply by 0.0167; C-reactive protein to milligram per liter, multiply by 10; D-dimer to nanomole
10 per liter, multiply by 0.0054; leukocytes to ×10⁹ per liter, multiply by 0.001.

11

Table 2 (on next page)

Performance indices for predicting ICU admission of the testing dataset

Performance indices for predicting ICU admission of the testing dataset. Abbreviations: area under the curve (AUC), accuracy, sensitivity, specificity, precision, recall, negative predictive value (NPV), positive predictive value (PPV) and F1 score (a harmonic mean of precision and recall).

1 **Table 2.** Performance indices for predicting ICU admission of the testing dataset. Abbreviations: area
2 under the curve (AUC), accuracy, sensitivity, specificity, precision, recall, negative predictive value
3 (NPV), positive predictive value (PPV) and F1 score (a harmonic mean of precision and recall).

	AUC	Accuracy	Sensitivity	Specificity	Precision	NPV	PPV	F1
Training	0.751	0.703	0.707	0.701	0.437	0.879	0.437	0.540
Testing	0.728	0.721	0.760	0.709	0.432	0.910	0.432	0.551

4
5
6
7
8

Table 3(on next page)

Demographic characteristics, comorbidities, symptoms, imaging findings, vital signs, and laboratory findings of death versus non-death (discharged).

Demographic characteristics, comorbidities, symptoms, imaging findings, vital signs, and laboratory findings of death versus non-death (discharged). Group comparison of categorical variables in frequencies and percentages used χ^2 or Fisher exact tests. Group comparison of continuous variables in medians and interquartile ranges (IQR) used the Mann-Whitney U test.

- 1 **Table 3.** Demographic characteristics, comorbidities, symptoms, imaging findings, vital signs, and
 2 laboratory findings of death versus non-death (discharged). Group comparison of categorical variables in
 3 frequencies and percentages used χ^2 or Fisher exact tests. Group comparison of continuous variables in
 4 medians and interquartile ranges (IQR) used the Mann-Whitney U test.

	Patients, No. (%)		p value
	Death (n=142)	Non-death (n=880)	
Demographics			
Age, median (range), y	76 (66,84)	59 (49,72)	<0.001
Sex			0.022
Male	93 (65.5%)	484 (55.0%)	
Female	49 (34.5%)	396 (45.0%)	
Ethnicity			0.001
Hispanic/Latino	23 (16.2%)	251 (28.5%)	
Non-Hispanic/Latino	105 (73.9%)	504 (57.3%)	
Unknown	14 (9.9%)	125 (14.2%)	
Race			0.023
Caucasian	91 (64.1%)	450 (51.1%)	
African American	6 (4.2%)	61 (6.9%)	
Asian	9 (6.3%)	33 (3.8%)	
American Indian/Alaska Native	1 (0.7%)	2 (0.2%)	
Native Hawaiian or other Pacific Islander	0	1 (0.1%)	
More than One Race	0	5 (0.6%)	
Unknown/Not Reported	35 (24.6%)	328 (37.3%)	
Comorbidities			
Smoking history	52 (36.6%)	204 (23.2%)	0.001
Diabetes	48 (33.8%)	229 (26.1%)	0.067
Hypertension	92 (64.8%)	402 (45.8%)	<0.001
Asthma	6 (4.2%)	51 (5.8%)	0.557
COPD	23 (16.2%)	66 (7.5%)	0.002
Coronary artery disease	39 (27.5%)	115 (13.1%)	<0.001
Heart failure	29 (20.4%)	47 (5.4%)	<0.001
Cancer	19 (13.4%)	78 (8.9%)	0.092
Immunosuppression	8 (5.6%)	65 (7.4%)	0.598
Chronic kidney disease	20 (14.1%)	75 (8.5%)	0.043
Symptoms			
Fever	81 (57.0%)	599 (68.1%)	0.012
Cough	73 (51.4%)	628 (71.4%)	<0.001
Shortness of breath	102 (71.8%)	594 (67.5%)	0.333
Fatigue	19 (13.4%)	216 (24.5%)	0.003
Sputum	10 (7.0%)	58 (6.6%)	0.856
Myalgia	15 (10.6%)	220 (25.0%)	<0.001
Diarrhea	27 (19.0%)	211 (24.0%)	0.239
Nausea or vomiting	10 (7.0%)	192 (21.8%)	<0.001

Sore throat	7 (4.9%)	69 (7.8%)	0.300
Rhinorrhea	4 (2.8%)	41 (4.7%)	0.386
Loss of smell	2 (1.4%)	38 (4.3%)	0.106
Loss of taste	2 (1.4%)	48 (5.5%)	0.035
Headache	7 (4.9%)	90 (10.2%)	0.045
Chest discomfort or chest pain	10 (7.0%)	151 (17.2%)	0.001
Imaging studies			
Abnormal chest x-ray results	123 (87.2%)	720 (84.6%)	0.524
Chest x-ray findings			0.214
Unilateral	18 (14.6%)	142 (19.7%)	
Bilateral	105 (85.4%)	577 (80.3%)	
Vital signs, median (IQR)			
Heart Rate, bpm	96 (81, 115)	99 (85, 110)	0.496
Respiratory rate, rate/min	24 (20, 32)	20 (18, 24)	<0.001
SpO ₂ %	93 (88, 96)	94 (92, 96)	<0.001
Systolic blood pressure, mmHg	127 (105, 142)	125 (113, 143)	0.568
Temperature, °C	37.1 (36.7, 37.6)	37.3 (36.9, 38.1)	<0.001
Laboratory findings at admission, median (IQR)			
Alanine aminotransferase, U/L	30.0 (17.0, 54.0)	30.0 (18.0, 52.0)	0.666
Brain natriuretic peptide, pg/mL	1652 (452, 4556)	164 (47, 772)	<0.001
C-reactive protein, mg/dL	13.4 (6.9, 21.8)	7.5 (3.2, 13.4)	<0.001
D-dimer, ng/mL	635 (365, 1753)	333 (213, 606)	<0.001
Ferritin, ng/mL	981 (442, 1657)	640 (308, 1333)	<0.001
Lactate dehydrogenase, U/L	436 (330, 638)	333 (257, 434)	<0.001
WBC, x10 ³ /ml	8.7 (6.4, 12.3)	7.3 (5.5, 9.5)	0.001
Lymphocytes%	8.9 (5.3, 13.6)	13.3 (8.7, 19.4)	<0.001
Procalcitonin, ng/mL	0.34 (0.18, 1.26)	0.15 (0.090, 0.28)	<0.001
Troponin, ng/mL	0.02 (0.01, 0.07)	0.01 (0.01, 0.01)	<0.001

5 Abbreviation: COPD, chronic obstructive pulmonary disease. IQR, interquartile range. SpO₂, oxygen
6 saturation.

7

8 SI conversion factors: To convert alanine aminotransferase and lactate dehydrogenase to microkatal per
9 liter, multiply by 0.0167; C-reactive protein to milligram per liter, multiply by 10; D-dimer to nanomole
10 per liter, multiply by 0.0054; leukocytes to ×10⁹ per liter, multiply by 0.001.

11

Table 4(on next page)

Performance indices for predicting mortality

Performance indices for predicting mortality of the testing dataset. Abbreviations: area under the curve (AUC), accuracy, sensitivity, specificity, precision, recall, negative predictive value (NPV), positive predictive value (PPV) and F1 score (a harmonic mean of precision and recall).

1 **Table 4.** Performance indices for predicting mortality of the testing dataset. Abbreviations: area under the
2 curve (AUC), accuracy, sensitivity, specificity, precision, recall, negative predictive value (NPV),
3 positive predictive value (PPV) and F1 score (a harmonic mean of precision and recall).

	AUC	Accuracy	Sensitivity	Specificity	Precision	NPV	PPV	F1
Training	0.852	0.892	0.706	0.922	0.589	0.952	0.589	0.642
Testing	0.844	0.853	0.750	0.872	0.522	0.949	0.522	0.616

4
5
6
7